Eli Lilly (LLY) Stock Eyes Price Breakout as Q4 Results Loom
Eli Lilly (LLY) investors should expect fireworks this week as the pharma giant prepares to drop its bombshell Q4 2024 earnings figures before
What Analysts Think of Eli Lilly Stock Ahead of Earnings
Key Takeaways Pharmaceutical company Eli Lilly is expected to report fourth-quarter earnings before the bell Thursday.Analysts tracking the company see increased sales and profit for Eli Lilly in the first full period in which its weight-loss drugs ceased to be in shortage.
Eli Lilly Stock Before Q4 Earnings: To Buy or Not to Buy?
Eli Lilly and Company LLY will report its fourth-quarter and full-year 2024 earnings on Feb. 6, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $13.72 billion and $5.15 per share, respectively. Earnings estimates for 2025 have declined from $24.05 to $23.57 per share over the past 30 days.
Eli Lilly Bulls Take Charge Ahead Of Q4 — Can It Reach $1000?
Eli Lilly (LLY) reports Q4 earnings Thursday. LLY stock up 8.22% YTD. Chart shows strong bullish momentum with potential for further gains. Analysts see 27% upside.
Eli Lilly & Co (LLY) Gets a Buy from Jefferies
Jefferies analyst Akash Tewari maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on February 3 and set a price target of
Erste Group raises Eli Lilly stock rating to Buy, sees strong sales
Erste Group analysts upgraded Eli Lilly stock from Hold to Buy, citing a robust product demand and a promising pipeline of potential successes. The analysts highlighted the pharmaceutical company's significant sales growth expected this year along with a positive earnings outlook.
Eli Lilly Shares Fall After GLP-1 Sales Miss Expectations. Is the Stock in Trouble?
When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep correction. Lilly is by no means in bad shape, but because the stock's price has become so inflated in recent years, so have expectations.
Eli Lilly Q4 2024 Earnings Preview: All eyes on stronger 2025
Eli Lilly (NYSE:LLY) is scheduled to announce Q4 earnings results on Thursday, February 6th, before market open. The consensus EPS Estimate is $5.11 (+105.2% Y/Y) and the consensus Revenue Estimate is $13.
Lilly needs a plan to spur weight-loss drug sales, investors say
Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...
Eli Lilly Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Analysts expect the Indianapolis, Indiana-based company to report quarterly earnings at $5.08 per share, up from $2.49 per share in the year-ago period. Eli Lilly projects quarterly revenue of $13.43 ...
MM&M18h
Inside Eli Lilly’s bold breast cancer awareness ad debut at the Grammys
Eli Lilly’s latest TV ad, unveiled during the Grammys on Sunday night, highlights the importance of early diagnosis for ...
Eli Lilly's head of obesity talks weight-loss innovations for 2025 — from an Ozempic-like pill to a triple-threat shot
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
With Zepbound Not Matching Expectations, Should Investors Give Up on Eli Lilly?
It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or analysts anticipated, resulting in ...
Eli Lilly's SWOT analysis: stock poised for growth amid challenges
Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $732 billion, has been ...
Eli Lilly price target raised to $1,038 from $1,029 at Truist
Truist raised the firm’s price target on Eli Lilly (LLY) to $1,038 from $1,029 and keeps a Buy rating on the shares. The firm is updating its ...